Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Processa Pharmaceuticals ( (PCSA) ) has issued an update.
On June 17, 2025, Processa Pharmaceuticals announced a binding term sheet with Intact Therapeutics, granting Intact an exclusive option to license PCS12852, a promising 5-HT4 receptor agonist for gastroparesis and other gastrointestinal disorders. The agreement includes $2.5 million in near-term payments, up to $452.5 million in milestone payments, double-digit royalties, and a 3.5% equity stake in Intact. This partnership is expected to unlock the value of Processa’s non-oncology assets while Intact aims to advance PCS12852 towards commercialization, addressing significant unmet needs in gastrointestinal treatments.
The most recent analyst rating on (PCSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Processa Pharmaceuticals stock, see the PCSA Stock Forecast page.
Spark’s Take on PCSA Stock
According to Spark, TipRanks’ AI Analyst, PCSA is a Underperform.
Processa Pharmaceuticals is facing significant financial challenges with no revenue generation and ongoing losses. Technical indicators point to bearish momentum, and valuation metrics highlight the high-risk nature typical of early-stage biotech firms. The company’s reliance on external financing for sustainability remains a concern.
To see Spark’s full report on PCSA stock, click here.
More about Processa Pharmaceuticals
Processa Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing Next Generation Cancer (NGC) drugs with improved safety and efficacy. Their strategy involves modifying existing FDA-approved oncology therapies to enhance their metabolism and distribution while maintaining their cancer-killing mechanisms. This approach aims to provide more effective and tolerable cancer treatments through an efficient regulatory path.
Average Trading Volume: 4,715,993
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.68M
See more insights into PCSA stock on TipRanks’ Stock Analysis page.